Nocturnal Scratch as a Digital Endpoint for Atopic Dermatitis: A Public launch event
September 8, 2022
For the first time ever, we have a blueprint for developing and deploying digital endpoints in medical product development.
On Sept. 8, industry leaders Abbvie, Janssen, Novartis, Pfizer, UCB, Advancing Innovation in Dermatology, Almirall, GSK, Leo Pharma, Eli Lilly, and Sanofi collaborated to research the meaningfulness of nocturnal scratching to atopic dermatitis (AD) patients and developed new resources for deploying scratch digital measures in clinical trials.
In addition to addressing an unmet need for AD patients, this work lays the groundwork for advancing the use of digital endpoints in medical research and care. Event attendees learned about:
- Results from a study on the meaningfulness of nocturnal scratch as a digital endpoint for AD patients
- Best practices, definitions, and additional resources for understanding what good digital endpoint development and deployment look like
- New tools that help you move beyond “what endpoints exist to measure?” to “I will use and measure this digital endpoint.”
- What additional work is being done to advance the use of digital endpoints in medical research and care
DiMe’s own, Lucy Cenakova, moderated a panel with Matthew Diamond, Chief Medical Officer at FDA, and Thorsten Vetter, Senior Scientific Officer at EMA.